Skip to content
THURSDAY, NOVEMBER 19, 2026

Independently reported.

Health

Heightmaxxing and erdafitinib: what the evidence says about a bladder cancer drug and teen height

Teens are reportedly buying the drug online to grow taller. Its label lists growth plate injuries in children, and the height evidence is a handful of case reports from young cancer patients.

By Eli Okafor, Health & Wellness

· 5 min read

An amber prescription pill bottle with spilled white tablets on a bedroom desk beside a tape measure and a smartphone.
Illustration: Trestlewire

At a glance

  • •Erdafitinib is approved only for adults with FGFR3-altered bladder cancer, and its label says pediatric safety and effectiveness are not established.
  • •The label records epiphysiolysis, bone fractures, slipped capital femoral epiphysis and accelerated linear growth in young patients; Johnson & Johnson reports growth disorders in 36.4 percent of children in one pediatric trial.
  • •The evidence for height gain is a few case reports in children with tumors, and the one detailed hip case involved a boy whose tumor and weight gain also affect the picture.
  • •Adult label data show eye problems in 22 percent and raised phosphate in 73 percent of patients, managed with monitoring that online buyers do not get.

Erdafitinib is approved in the United States for one purpose. The label covers adults with locally advanced or metastatic bladder cancer whose tumors carry certain FGFR3 gene changes and who have already progressed on earlier treatment. It also says safety and effectiveness in pediatric patients have not been established. That is the documented baseline for a pill that teenage boys are now reportedly buying on the black market to grow taller, in a social media trend called heightmaxxing.

Fox News has reported on the trend. It says teens, mostly boys, discuss the drug online as "ERDA" or "Erta" after reading claims that it adds height. Johnson & Johnson, whose Janssen unit holds the Balversa label, told reporters the drug has never been approved to stimulate growth, according to Fox. None of the reporting I could load puts a number on how many teens are actually taking it. The size of the trend rests on online chatter and anecdote.

What does the drug do to a growing skeleton?

The prescribing information answers this in section 8.4. In a study of patients aged 6 to under 18 with FGFR-positive advanced solid tumors, epiphysiolysis and bone fractures occurred. Epiphysiolysis is a separation at the growth plate. After approval, the label adds, cases of slipped capital femoral epiphysis and accelerated linear growth were reported in treated patients, in the postmarket setting and in the literature.

Johnson & Johnson's medical information page gives a size for the same finding. In its pediatric tumor trial, listed as NCT04083976, growth disorders were an adverse event unique to children, at 36.4 percent. Those were children with cancer, dosed under oncology supervision. They were not healthy teenagers.

36.4%

of children in a pediatric Balversa trial had a growth disorder

Reported by Johnson & Johnson Medical Connect. Participants were children with advanced tumors, not healthy teens.

Why would a cancer drug make anyone taller?

Dr. Stephanie Widmer, an emergency physician in New York City and a Fox News medical contributor, told the network that the drug blocks signaling pathways involved in cancer cell growth. Those same pathways play a part in bone development, she said, which may explain why some children on the drug grew unexpectedly fast. The explanation is a physician's working theory, not a settled mechanism for healthy adolescents.

The human evidence behind it is thin. Fox cites a 2024 paper in Hormone Research in Paediatrics that described accelerated growth in two pediatric patients, and a separate case report of a teenager who grew more than 5 inches during treatment and developed serious skeletal complications. That is three patients, all with tumors, none replicated in a trial built to measure height.

“These drugs were developed to treat serious medical conditions, not to enhance physical appearance”

Dr. Stephanie Widmer, emergency medicine physician, New York City, and Fox News medical contributor

A 2024 case report from Cancer Care Manitoba shows what the complication looks like. A 13-year-old boy with an optic pathway and hypothalamic glioma developed persistent knee pain 12 weeks into erdafitinib. An X-ray showed a slipped capital femoral epiphysis, a hip problem at the growth plate, and he had surgical pinning of the right hip. His tumor shrank 30 percent. He also had rapid weight gain and a BMI above 30 from the tumor's location, so the case cannot isolate the drug as the only cause. The authors, though, call it an on-target skeletal toxicity and recommend regular skeletal monitoring for children on this class of drug.

Dr. Jessica Gray, a family physician in Lubbock, Texas, told Fox that forced, rapid growth is not the same as healthy bone growth and can lead to premature growth plate damage and fractures.

What else is on the label that a teenager would not see coming?

The adverse reaction data come from adults with bladder cancer, so they set a floor, not a forecast for teens. Even so, they are specific. Central serous retinopathy, a fluid buildup under the retina that can cause a visual field defect, occurred in 22 percent of patients, with a median onset of 46 days. Increased phosphate occurred in 73 percent, with a median onset of 16 days. The label ties high phosphate to soft tissue mineralization and cutaneous calcinosis, and lists nail disorders and mouth sores among the most common reactions.

Patients in the approved setting are managed around those risks. The label tells prescribers to restrict phosphate intake to 600 to 800 mg daily, use phosphate binders when levels climb, and adjust doses by eye exam findings. A teenager ordering pills online has no prescriber running any of that.

Is anyone testing FGFR drugs for height on purpose?

Yes, in a different drug and a different population. ClinicalTrials.gov lists a completed phase 2 study of infigratinib in children with achondroplasia, NCT04265651, with 84 participants enrolled. A second study, NCT06873035, tests the same drug in children with hypochondroplasia. It is phase 2/3, enrolling by invitation, with 24 participants estimated. Both involve diagnosed skeletal conditions and trial monitoring. I did not review their results, and they say nothing about erdafitinib in healthy adolescents.

Can the drug reopen a closed growth plate?

Widmer told Fox that once growth plates close near the end of puberty, no medication can reopen them. By her account, older teens taking the drug would carry the risks with no possible height gain. That is one physician's statement to a news network, not a measured finding.

The next data point to watch is the hypochondroplasia trial, still enrolling, which will show what a supervised FGFR inhibitor does to growth in children who have a diagnosed reason to take one.

Frequently Asked Questions

Is erdafitinib approved to make children taller?
No. The label covers adults with locally advanced or metastatic bladder cancer with susceptible FGFR3 alterations. It states that safety and effectiveness in pediatric patients have not been established.
What is heightmaxxing?
Fox News describes it as a social media trend in which teens, mostly boys, try to increase their height, including by obtaining erdafitinib on the black market. No count of how many teens are doing so has been published in the reporting reviewed.
What does the evidence say about growth in children taking the drug?
The label records accelerated linear growth and slipped capital femoral epiphysis in postmarket reports and the literature. The published cases are children with tumors, a handful of patients per report, and none was designed to measure height in healthy adolescents.
  • erdafitinib
  • heightmaxxing
  • Balversa
  • growth plates
  • Johnson & Johnson
  • teen health

Sources

  1. 01Viral 'heightmaxxing' trend has teen boys taking cancer drugs to grow taller, doctors warn of risks, Fox Newsfoxnews.com
  2. 02Balversa (erdafitinib) prescribing information, DailyMed, National Library of Medicinedailymed.nlm.nih.gov
  3. 03Use of Balversa in pediatric patients, Johnson & Johnson Medical Connectjnjmedicalconnect.com
  4. 04Case report: slipped capital femoral epiphysis with FGFR tyrosine kinase inhibitor therapy in a child, Frontiers in Oncologyfrontiersin.org
  5. 05Study of infigratinib in children with achondroplasia (NCT04265651), ClinicalTrials.govclinicaltrials.gov
  6. 06Interventional study of infigratinib in children with hypochondroplasia (NCT06873035), ClinicalTrials.govclinicaltrials.gov

Corrections

No corrections have been made to this article.

About the reporter

Eli Okafor

Health & Wellness Reporter, Trestlewire

I am not a physician, and nothing I write is medical advice. I say that first because it shapes everything else.

Read full bio and all stories →

The Morning Wire

The day’s reporting, in your inbox before nine.

Free. Unsubscribe any time. We never share your address.